Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors hMT1 and hMT2
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032863 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mattia Cantarini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department DISVA, Università Politecnica delle Marche, Via Brecce Bianche, 60131 Ancona, Italy. Hauptthemen laut MEDLINE: Receptor, Melatonin, MT1, Melatonin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glaucoma, a major ocular neuropathy originating from a progressive degeneration of retinal ganglion cells, is often associated with increased intraocular pressure (IOP). Daily IOP fluctuations are physiologically influenced by the antioxidant and signaling activities of melatonin. This endogenous modulator has limited employment in treating altered IOP disorders due to its low stability and bioavailability. The search for low-toxic compounds as potential melatonin agonists with higher stability and bioavailability than melatonin itself could start only from knowing the molecular basis of melatonergic activity. Thus, using a computational approach, we studied the melatonin binding toward its natural macromolecular targets, namely melatonin receptors 1 (MT1) and 2 (MT2), both involved in IOP signaling regulation. Besides, agomelatine, a melatonin-derivative agonist and, at the same time, an atypical antidepressant, was also included in the study due to its powerful IOP-lowering effects. For both ligands, we evaluated both stability and ligand positioning inside the orthosteric site of MTs, mapping the main molecular interactions responsible for receptor activation. Affinity values in terms of free binding energy (ΔGbind) were calculated for the selected poses of the chosen compounds after stabilization through a dynamic molecular docking protocol. The results were compared with experimental in vivo effects, showing a higher potency and more durable effect for agomelatine with respect to melatonin, which could be ascribed both to its higher affinity for hMT2 and to its additional activity as an antagonist for the serotonin receptor 5-HT2c, in agreement with the in silico results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department DISVA, Università Politecnica delle Marche, Via Brecce Bianche, 60131 Ancona, Italy.
- Fidia Pharma Group, Research Center, 95100 Catania, Italy.
- Department of Biology, University of Pisa, 56127 Pisa, Italy.
- Department SIMAU, Università Politecnica delle Marche, Via Brecce Bianche, 60131 Ancona, Italy.
ORCID-Profile: Dario Rusciano, Rosario Amato, Maurizio Cammalleri, Massimo Dal Monte, Cristina Minnelli, Emiliano Laudadio, Giovanna Mobbili, Roberta Galeazzi
Zitieren
APA
Cantarini, M., Rusciano, D., Amato, R., Canovai, A., Cammalleri, M., Monte, M. D., Minnelli, C., Laudadio, E., Mobbili, G., Giorgini, G., & Galeazzi, R. (2023). Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors hMT1 and hMT2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032863
Vancouver
Cantarini M, Rusciano D, Amato R, Canovai A, Cammalleri M, Monte MD, et al. Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors hMT1 and hMT2. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032863
BibTeX
@article{Cantarini2023,
author = {Cantarini, Mattia and Rusciano, Dario and Amato, Rosario and Canovai, Alessio and Cammalleri, Maurizio and Monte, Massimo Dal and Minnelli, Cristina and Laudadio, Emiliano and Mobbili, Giovanna and Giorgini, Giorgia and Galeazzi, Roberta},
title = {Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors hMT1 and hMT2},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032863}
}
EUVIMED